Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.56 |
| ▸ | PLK1 | P53350 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PYGL | P06737 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14880129 | 0.86 | HDAC1 (0.59) | TAS1R3TAS1R1PKMCA1CA2 | |
| SCHEMBL12062652 | 0.86 | TAS1R3 (0.60) | TAS1R3TAS1R1PLK1HPGDALDH1A1 | |
| SCHEMBL4151619 | 0.85 | CYP1A2 (0.66) | PLK1HPGDALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL12937578 | 0.84 | TAS1R3 (0.58) | TAS1R3TAS1R1ALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL13947173 | 0.84 | TAS1R3 (0.55) | TAS1R3TAS1R1HPGDALDH1A1PKM | |
| SCHEMBL29161867 | 0.83 | TAS1R3 (0.53) | TAS1R3TAS1R1HPGDALDH1A1PKM | |
| SCHEMBL5758000 | 0.82 | MEN1 (0.68) | PLK1HPGDALDH1A1MAPTALOX15 | |
| SCHEMBL31721306 | 0.81 | MAPT (0.64) | TAS1R3TAS1R1HPGDALDH1A1MAPT | |
| SCHEMBL1757167 | 0.81 | MAPT (0.64) | TAS1R3TAS1R1HPGDALDH1A1MAPT | |
| SCHEMBL12125066 | 0.81 | PLK1 (0.58) | TAS1R3TAS1R1PLK1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922841-B1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2017-06-07 | — | — | EP | disclosed |
| US-20160250212-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-09-01 | — | — | US | disclosed |
| US-9315494-B2 | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-19 | — | — | US | disclosed |
| WO-2015058031-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20140045869-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-13 | — | — | US | disclosed |
| WO-2013163190-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20130281431-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-8361998-B2 | Compounds and their use as IKACh blockers | ASTRAZENECA AB | 2013-01-29 | — | — | US | disclosed |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| EP-1784399-B1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-7910585-B2 | Pyrimidine derivatives | NOVARTIS AG (CH) | 2011-03-22 | — | — | US | disclosed |
| US-7910585-B2 | Pyrimidine derivatives | NOVARTIS AG (CH) | 2011-03-22 | — | — | US | disclosed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20080293708-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| US-20080293708-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045869-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | TAS1R3 3950/4885TAS1R1 3727/4885PLK1 53/4885 |
| US-20160250212-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | TAS1R3 3950/4885TAS1R1 3727/4885PLK1 53/4885 |
| US-20130281431-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | TAS1R3 3950/4885TAS1R1 3727/4885PLK1 53/4885 |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | TAS1R3 3687/4885TAS1R1 3249/4885PLK1 1907/4885 |
| US-20080293708-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | TAS1R3 2704/4885TAS1R1 2512/4885PLK1 643/4885 |
| US-20090131436-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | TAS1R3 2381/4885TAS1R1 2199/4885PLK1 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.